Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company ... into ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...

Think of biotech and the bioeconomy as a broad methodology encompassing all those who use and borrow from biology to produce ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

A scientist who was diagnosed with stage 3 cancer treated herself using lab-grown viruses, a method researchers say is 'not ...

Scientists uncovered a previously unrecognized tumor suppression mechanism through the study of condensates and ribosome formation.

Abeona Therapeutics (ABEO) announced the FDA has accepted for review resubmission of Biologics License Application for prademagene ...